166 related articles for article (PubMed ID: 37577240)
1. Therapeutic Effect of Prolyl Endopeptidase Inhibitor in High-fat Diet-induced Metabolic Dysfunction-associated Fatty Liver Disease.
Zhang JB; Li MT; Lin SZ; Cheng YQ; Fan JG; Chen YW
J Clin Transl Hepatol; 2023 Oct; 11(5):1035-1049. PubMed ID: 37577240
[TBL] [Abstract][Full Text] [Related]
2. Prolyl endopeptidase gene disruption attenuates high fat diet-induced nonalcoholic fatty liver disease in mice by improving hepatic steatosis and inflammation.
Jiang DX; Zhang JB; Li MT; Lin SZ; Wang YQ; Chen YW; Fan JG
Ann Transl Med; 2020 Mar; 8(5):218. PubMed ID: 32309365
[TBL] [Abstract][Full Text] [Related]
3. Prolyl Endopeptidase Gene Disruption Improves Gut Dysbiosis and Non-alcoholic Fatty Liver Disease in Mice Induced by a High-Fat Diet.
Jiang D; Zhang J; Lin S; Wang Y; Chen Y; Fan J
Front Cell Dev Biol; 2021; 9():628143. PubMed ID: 34095107
[TBL] [Abstract][Full Text] [Related]
4. Prolyl endopeptidase disruption reduces hepatic inflammation and oxidative stress in methionine-choline-deficient diet-induced steatohepatitis.
Zhang J; Jiang D; Lin S; Cheng Y; Pan J; Ding W; Chen Y; Fan J
Life Sci; 2021 Apr; 270():119131. PubMed ID: 33516698
[TBL] [Abstract][Full Text] [Related]
5. N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Mitigates Experimental Colitis Through Inhibition of Intestinal Mucosal Inflammatory Responses
Shi Y; Zhou M; Yan J; Gong Z; Wu J; Chen Y; Chen Y
Front Pharmacol; 2020; 11():593. PubMed ID: 32435194
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Prolyl Oligopeptidase Restores Spontaneous Motor Behavior in the α-Synuclein Virus Vector-Based Parkinson's Disease Mouse Model by Decreasing α-Synuclein Oligomeric Species in Mouse Brain.
Svarcbahs R; Julku UH; Myöhänen TT
J Neurosci; 2016 Dec; 36(49):12485-12497. PubMed ID: 27927963
[TBL] [Abstract][Full Text] [Related]
7. Treatment of traumatic brain injury in rats with N-acetyl-seryl-aspartyl-lysyl-proline.
Zhang Y; Zhang ZG; Chopp M; Meng Y; Zhang L; Mahmood A; Xiong Y
J Neurosurg; 2017 Mar; 126(3):782-795. PubMed ID: 28245754
[TBL] [Abstract][Full Text] [Related]
8. Quantitative proteomics analysis based on data-independent acquisition reveals the effect of Shenling Baizhu powder (SLP) on protein expression in MAFLD rat liver tissue.
Song S; Zheng J; Zhao D; Zheng A; Zhu Y; Xu Q; Liu T
Clin Proteomics; 2023 Dec; 20(1):55. PubMed ID: 38036981
[TBL] [Abstract][Full Text] [Related]
9. Glutamine prevents high-fat diet-induced hepatic lipid accumulation in mice by modulating lipolysis and oxidative stress.
Zhang Y; Wang Y; Liao X; Liu T; Yang F; Yang K; Zhou Z; Fu Y; Fu T; Sysa A; Chen X; Shen Y; Lyu J; Zhao Q
Nutr Metab (Lond); 2024 Mar; 21(1):12. PubMed ID: 38459503
[TBL] [Abstract][Full Text] [Related]
10. Si-Ni-San reduces lipid droplet deposition associated with decreased YAP1 in metabolic dysfunction-associated fatty liver disease.
Zheng K; Zhou W; Ji J; Xue Y; Liu Y; Li C; Zhang Z; Lu J; Shi X; Li Y
J Ethnopharmacol; 2023 Apr; 305():116081. PubMed ID: 36608777
[TBL] [Abstract][Full Text] [Related]
11. A prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease.
Myöhänen TT; Hannula MJ; Van Elzen R; Gerard M; Van Der Veken P; García-Horsman JA; Baekelandt V; Männistö PT; Lambeir AM
Br J Pharmacol; 2012 Jun; 166(3):1097-113. PubMed ID: 22233220
[TBL] [Abstract][Full Text] [Related]
12. Jiuzhuan Huangjing Pills relieve mitochondrial dysfunction and attenuate high-fat diet-induced metabolic dysfunction-associated fatty liver disease.
Mu JK; Zi L; Li YQ; Yu LP; Cui ZG; Shi TT; Zhang F; Gu W; Hao JJ; Yu J; Yang XX
Biomed Pharmacother; 2021 Oct; 142():112092. PubMed ID: 34449316
[TBL] [Abstract][Full Text] [Related]
13. Protective and Therapeutic Effects of Orlistat on Metabolic Syndrome and Oxidative Stress in High-Fat Diet-Induced Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) in Rats: Role on Nrf2 Activation.
Zakaria Z; Othman ZA; Bagi Suleiman J; Jalil NAC; Ghazali WSW; Mohamed M
Vet Sci; 2021 Nov; 8(11):. PubMed ID: 34822647
[TBL] [Abstract][Full Text] [Related]
14. The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse.
Savolainen MH; Richie CT; Harvey BK; Männistö PT; Maguire-Zeiss KA; Myöhänen TT
Neurobiol Dis; 2014 Aug; 68():1-15. PubMed ID: 24746855
[TBL] [Abstract][Full Text] [Related]
15. Hepatoprotective Effect of Bee Bread in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Rats: Impact on Oxidative Stress and Inflammation.
Zakaria Z; Othman ZA; Suleiman JB; Che Jalil NA; Ghazali WSW; Nna VU; Mohamed M
Antioxidants (Basel); 2021 Dec; 10(12):. PubMed ID: 34943134
[TBL] [Abstract][Full Text] [Related]
16.
Yu LP; Li YJ; Wang T; Tao YX; Zhang M; Gu W; Yu J; Yang XX
World J Gastroenterol; 2023 Jan; 29(1):171-189. PubMed ID: 36683716
[TBL] [Abstract][Full Text] [Related]
17. KYP-2047 penetrates mouse brain and effectively inhibits mouse prolyl oligopeptidase.
Jalkanen AJ; Leikas JV; Forsberg MM
Basic Clin Pharmacol Toxicol; 2014 Jun; 114(6):460-3. PubMed ID: 24350801
[TBL] [Abstract][Full Text] [Related]
18. Network pharmacology-based identification of significant pathway for protection of Yinhuang granule in a mice model of metabolic-associated fatty liver disease.
Yan S; Zhang S; Du A; Miao H; Lu B; Huang Z; Ji L
Phytomedicine; 2021 Oct; 91():153666. PubMed ID: 34339944
[TBL] [Abstract][Full Text] [Related]
19. Antifibrotic effect of N-acetyl-seryl-aspartyl-lysyl-proline on bile duct ligation induced liver fibrosis in rats.
Zhang L; Xu LM; Chen YW; Ni QW; Zhou M; Qu CY; Zhang Y
World J Gastroenterol; 2012 Oct; 18(37):5283-8. PubMed ID: 23066324
[TBL] [Abstract][Full Text] [Related]
20. Vitamin C and vitamin D
Chen Q; Zhao L; Mei L; Zhao X; Han P; Liu J; Meng C; Li R; Zhong R; Wang K; Li J
Front Pharmacol; 2023; 14():1163694. PubMed ID: 37089915
[No Abstract] [Full Text] [Related]
[Next] [New Search]
